Innovate Biopharmaceuticals is a clinical-stage biotechnology company dedicated to developing innovative therapies for autoimmune and inflammatory diseases that currently lack effective treatments. The company’s pipeline includes several drug candidates targeting conditions such as celiac disease, nonalcoholic steatohepatitis (NASH), Crohn’s disease, and ulcerative colitis. Notably, INN-202 is advancing into Phase 3 trials for celiac disease and has received Fast Track designation, while INN-217 and INN-289 are in earlier phases of development for NASH and Crohn’s disease, respectively. The company holds global rights to its products, supported by a robust portfolio of over 150 patents worldwide, which underscores its commitment to bringing novel therapeutics to market.

The technologies employed by Innovate Biopharmaceuticals focus on creating targeted treatments that address the underlying mechanisms of autoimmune and inflammatory diseases. Their approach includes developing formulations that enhance patient compliance, such as INN-108, which is designed for inflammatory bowel disorders in a convenient liquid form. Additionally, the company is exploring advanced imaging techniques with INN-329, aimed at improving diagnostic capabilities for conditions like magnetic resonance cholangiopancreatography (MRCP). Through these innovative therapies, Innovate Biopharmaceuticals aims to provide effective solutions for patients suffering from complex health issues, ultimately striving to improve their quality of life.

United States

Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases with unmet needs. Their pipeline includes drug candidates for celiac disease, NASH, Crohn's, and ulcerative colitis.

Innovate Biopharmaceuticals

Company Details